Contents
Academy · Medical writing · High-impact research paper
How to Write a High-Impact Medical Research Paper: Reporting Guidelines, ICMJE Requirements and Editorial Decisions
Most of the factors that determine publishability are documented: the reporting guideline for the study design, the ICMJE conditions and the journal’s own instructions.
Writing for a high-impact journal consists largely of meeting documented requirements: the reporting guideline for the study design, the ICMJE conditions for consideration, and the target journal’s own instructions. This article sets out the current requirements and identifies the claims that the evidence does not support.
Definition of “high-impact”
The phrase has no definition of its own; it means scoring well on a metric, and the metrics have different owners and different databases.
Table 1. Organisations calculating the two most frequently cited journal metrics
| Metric | Owner | Published in | Derived from |
|---|---|---|---|
| Journal Impact Factor | Clarivate | Journal Citation Reports | Web of Science Core Collection |
| CiteScore | Elsevier | Scopus | Scopus |
Clarivate's own description of the source: “Journal Citation Reports is sourced from Web of Science Core Collection”11 Elsevier's, for CiteScore: “CiteScore metrics are a suite of indicators calculated from data in Scopus”12 Different corpora, different windows, different owners — so an impact factor and a CiteScore are not interchangeable figures. Our guide to journal metrics works through all five of them.
Selection of the reporting guideline by study design
The EQUATOR Network is “an international initiative that seeks to improve the reliability and value of published health research literature”7 by “promoting transparent and accurate reporting and wider use of robust reporting guidelines”7 — and it is the index to use when you need the right checklist for a design.
Table 2. The main reporting guidelines, current versions
| Guideline | Applies to | Checklist | Note |
|---|---|---|---|
| CONSORT 2025 | Randomised trials, reporting of results | 30 items in 6 sections | Supersedes CONSORT 2010, which its authors say should no longer be used. |
| SPIRIT 2025 | Randomised trial protocols | 34 items | A separate checklist for a separate document. The two executive groups have merged, which makes the two guidelines easy to conflate. |
| STROBE | Observational studies — cohort, case-control, cross-sectional | 22 items, 18 common and 4 design-specific | Current version 2007. Explicitly not a quality-assessment instrument. |
| PRISMA 2020 | Systematic reviews, with or without meta-analysis | 27 items in 7 sections | Replaces PRISMA 2009. |
PRISMA 2020's own statement of its scope: “The PRISMA 2020 checklist includes seven sections with 27 items”6, asking that “authors should prepare a transparent, complete, and accurate account of why the review was done, what they did”6 STROBE's: “a checklist of 22 items that we consider essential for good reporting of observational studies”5
Limitations of reporting checklists
The STROBE authors themselves note that “the checklist is not an instrument to evaluate the quality of observational research”. It governs the completeness of reporting rather than the quality of the study. Presenting a completed STROBE checklist as evidence of methodological quality misinterprets its purpose.
Replacement of CONSORT 2010 by CONSORT 2025
This is the change most likely to be missing from guidance you have read elsewhere, including, until this rewrite, from this page. Its authors put it without qualification: “The CONSORT 2025 statement supersedes the CONSORT 2010 statement, which should no longer be used.”4 and “Authors, editors, reviewers, and other potential users should use CONSORT 2025”4
The current checklist has 30 items in six sections, where CONSORT 2010 had 254. The practical differences for an author: several items from the Harms, Outcomes and Non-pharmacological Treatment extensions are now in the main checklist, and there is a new Open science section grouping trial registration, access to the protocol and analysis plan, data sharing, and funding and conflicts4.
Note also that SPIRIT 2025 is a separate checklist for trial protocols, with its own item count. The two executive groups have merged, which makes the pair easy to conflate, but they govern different documents at different stages. Our CONSORT 2025 guide covers the item-by-item changes.
ICMJE requirements for admissibility
Three ICMJE requirements can make a paper unpublishable rather than merely weak, which puts them in a different category from writing advice.
Authorship. ICMJE bases authorship on four criteria:
Table 3. The four ICMJE authorship criteria
| 1 | Substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data for the work. |
| 2 | Drafting the work or reviewing it critically for important intellectual content. |
| 3 | Final approval of the version to be published. |
| 4 | Agreement to be accountable for all aspects of the work, including ensuring that questions about the accuracy or integrity of any part are appropriately investigated and resolved. |
Requirement to meet all four authorship criteria
Authors must meet all four criteria, not any one of them. ICMJE states that “all those designated as authors should meet all four criteria”, and that contributors meeting fewer “should not be listed as authors”; such contributors are acknowledged instead, with their contribution specified. Funding a study, collecting the data or supervising the department does not in itself qualify a person for authorship.
ICMJE states that “All those designated as authors should meet all four criteria for authorship”1, and that “Contributors who meet fewer than all 4 of the above criteria for authorship should not be listed as authors”1 — they are acknowledged instead, with their contribution specified.
Trial registration. ICMJE requires “registration of clinical trials in a public trials registry at or before the time of first patient consent”2 as “a condition of consideration for publication”2, and warns that “authors failing to prospectively register a trial risk its inadmissibility to our journals”2 This is the one item on this page with no remedy after the fact: a trial registered late is registered late, and no revision fixes it.
Conflicts of interest. Authors “they are responsible for disclosing all relationships and activities that might bias or be seen to bias their work”3 Note the standard: relationships that might be seen to bias the work are disclosable too, which makes the test considerably broader than actual influence.
Reasons for editorial rejection
Most papers submitted to selective journals are rejected, and most of those are rejected before review. The BMJ publishes its own figures: it accepts “only about 7% of the 7000-8000 articles we receive each year”8 and “just 4% of the ~4,000 research articles”8 It also states that “Roughly two thirds of all submissions are rejected without sending them for external peer review.”8 and that “About half the original research articles we receive are rejected at this stage, before sending out for review.”8
Different denominators for desk-rejection figures
The two desk-rejection figures have different denominators: approximately two-thirds of all submissions are rejected without external review, compared with about half of original research articles. Applying the larger figure to research papers would misrepresent the source.
The reasons, as stated by editors. An analysis of 369 manuscripts rejected before external review recorded why9:
Table 4. Editors’ reasons for not sending a manuscript for review
| Reason | Number | Share of 369 |
|---|---|---|
| Ineffective study question or design | 338 | 92% |
| Suboptimal data collection process | 180 | 49% |
| Weak discussion or conclusions | 139 | 37% |
| Topic unimportant or irrelevant to the journal’s mission | 137 | 37% |
| Weak data analysis or presentation of results | 120 | 33% |
| Text difficult to follow or understand | 89 | 24% |
| Inadequate or incomplete introduction | 67 | 18% |
| Issues with scientific conduct | 20 | 5% |
These percentages sum to considerably more than 100 because manuscripts were assigned an average of three or more reasons each. The study reports no total submission count, so it supports no desk-rejection rate, only the ranking of reasons. Moreover, it concerns a medical education journal: the ranking is credible and citable, but it does not represent clinical medical journals generally.9
And from reviewers. An earlier analysis of 1,053 negative reviewer comments found the largest single category was statistical10:
Table 5. Leading reasons in reviewers’ negative comments
| Reason | Share of comments |
|---|---|
| Statistics inappropriate, incomplete or poorly described | 11.2% |
| Overinterpretation of results | 8.7% |
| Inappropriate or suboptimal instrument | 7.3% |
| Sample too small or biased | 5.6% |
| Text difficult to follow | 3.9% |
| Insufficient or incomplete problem statement | 3.9% |
The same study looked at what reviewers praised in manuscripts they unanimously recommended for acceptance10:
Table 6. Factors cited by reviewers in accepted manuscripts
| Strength | Share of comments |
|---|---|
| An important or timely problem | 20.2% |
| Good writing | 18.3% |
| A well-designed study | 10.3% |
Which is a usefully deflating result: the top three strengths of accepted papers were an important problem, good writing and a well-designed study, in that order. As the author put it, “Scientific writing demands both conducting good science and writing good manuscripts.”10
The top twenty reasons accounted for about 70% of all negative comments, and the single largest category was statistical. As with Meyer and colleagues, this is medical education rather than clinical medicine, and the shares are of comments rather than of manuscripts.10 9
Claims not supported by the evidence
A claim not made in this article
This article deliberately does not make one frequently repeated claim: that adherence to a reporting guideline improves the probability of acceptance or increases citations. Neither claim could be verified. The one study whose title suggests such an effect, on adherence and citation counts, is an exploratory, post hoc, single-journal secondary analysis in which the intervention was adding a methodologist to the editorial process, not author adherence, and in which adherence was not measured directly; its authors describe the results as “promising, but not definitive”. The systematic reviews of guideline endorsement examine completeness of reporting rather than acceptance or citation, and describe their own included studies as methodologically weak. The evidence supports a narrower conclusion that nonetheless warrants action: reporting guidelines improve the completeness of reporting, editors and the ICMJE expect their use, and incomplete reporting is among the reasons editors cite for rejection.
Why spell this out on a page about writing high-impact papers? Because the unsupportable version of the claim is everywhere, and it leads authors to treat a checklist as a submission tactic rather than as what it is: a way of making sure the paper contains the information a reader needs to judge the work. Reporting completely is worth doing on its own merits, and the honest case for it does not need an invented acceptance statistic.
Recommended working practices
Practical application
- Register the trial before the first patient consents. No subsequent step can remedy a failure to do so.
- Confirm authorship against the four ICMJE criteria early and in writing, and acknowledge contributors who meet fewer than all four rather than listing them as authors.
- Identify the relevant reporting guideline on the EQUATOR Network before drafting, and work from its checklist rather than applying it retrospectively at submission.
- Report randomised trials according to CONSORT 2025 and its 30 items. CONSORT 2010 has been superseded, and its authors state that it should no longer be used.
- Treat journal scope as a primary consideration. A topic irrelevant to the journal’s mission was cited in 37% of pre-review rejections in one analysis, and no degree of refinement addresses it.
- Arrange for the statistical analysis to be reviewed by a statistician. Statistics constituted the largest single category of negative reviewer comments.
- Disclose all relationships that might be perceived as a source of bias, not only those the authors consider to have had an influence.
- Do not assume, or state in a cover letter, that adherence to a reporting guideline will secure acceptance. A reporting guideline should be used because it ensures complete reporting.
Key points
CONSORT 2025 supersedes CONSORT 2010 and has 30 items; STROBE has 22 and is explicitly not a quality-assessment tool; PRISMA 2020 has 27. ICMJE requires all four authorship criteria, registration at or before first patient consent, and disclosure of anything that might be seen to bias the work. Most submissions to selective journals are rejected before review, predominantly for an ineffective study question or design or for being out of scope. There is no verified evidence that adherence to a reporting guideline improves the probability of acceptance; complete reporting is warranted because it permits critical appraisal of the paper, not as a strategy for acceptance.
No. CONSORT 2025 supersedes it, and its authors state plainly that CONSORT 2010 “should no longer be used”. The current checklist has 30 items in six sections, not the 25 items of the 2010 version, and it adds a new Open science section covering registration, protocol and analysis-plan access, data sharing, and funding and conflicts.
CONSORT 2025 for reports of randomised trials, SPIRIT 2025 for randomised trial protocols, STROBE for observational studies (cohort, case-control and cross-sectional) and PRISMA 2020 for systematic reviews. The EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network maintains a searchable index, which should be consulted for an extension that corresponds more closely to the study design.
There is no verified evidence that it does, and this article does not imply otherwise. The evidence supports three conclusions: reporting guidelines improve the completeness of study reporting, editors and the ICMJE expect their use, and incomplete reporting is among the reasons editors give for rejection. These are sufficient reasons to use a reporting guideline. A higher acceptance rate is not a claim that can be supported by a source.
Substantial contribution to conception, design, acquisition, analysis or interpretation; drafting or critically reviewing the work for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work. ICMJE requires all four; contributors meeting fewer criteria should be acknowledged rather than listed as authors.
At or before the time of first patient consent. ICMJE makes registration in a public trials registry “a condition of consideration for publication”, and warns that authors who fail to register prospectively “risk its inadmissibility to our journals”. This is the only requirement described in this article that cannot be remedied later.
The majority, usually before review. The BMJ states that it publishes only about 7% of the 7,000 to 8,000 articles it receives each year, and only 4% of approximately 4,000 research articles. It also states that approximately two-thirds of all submissions are rejected without external peer review, and about half of original research articles.
Predominantly an ineffective study question or design. In an analysis of 369 manuscripts rejected before review at one journal, 92% were cited for an ineffective study question or design, 49% for a suboptimal data collection process, and 37% each for weak discussion or conclusions and for a topic irrelevant to the journal’s mission. Manuscripts were assigned an average of three or more reasons each.
Clarivate, which publishes it in Journal Citation Reports, using data from the Web of Science Core Collection. CiteScore is a different metric with a different owner: it is calculated by Scopus, which is owned by Elsevier, from the Scopus database. The two values are not comparable, and a journal’s rank may differ between them.
References
- International Committee of Medical Journal Editors. Defining the Role of Authors and Contributors, Section II.A.1. read 15 October 2026. View on ICMJEThe four authorship criteria, and the requirement that all four be met. The first and fourth criteria are longer than our tooling can quote in one piece, so they are given in full from the source rather than quoted in part.
- International Committee of Medical Journal Editors. Clinical Trial Registration, Section III.L.1. read 15 October 2026. View on ICMJERegistration before the first patient consents, as a condition of being considered for publication. The consequence of getting this wrong is that the paper becomes unpublishable in these journals, which no amount of later work fixes.
- International Committee of Medical Journal Editors. Author Responsibilities — Conflicts of Interest, Section II.B. read 15 October 2026. View on ICMJEThe disclosure standard, which covers relationships that might be seen to bias the work as well as those that do.
- Hopewell S, Chan A-W, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, et al., Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. doi:10.1136/bmj-2024-081123 read 15 October 2026. View on The BMJThe current version of record. Note the volume is 389: the official checklist PDF and the EQUATOR record both still print 388, which was the pre-pagination volume, so the wrong number is widely circulated.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Medicine. 2007;4(10):e296. read 15 October 2026. View on PLOS MedicineThe current version is 2007; no later revision was found. 22 items, of which 18 are common to cohort, case-control and cross-sectional designs and 4 are design-specific.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71 read 15 October 2026. View on The BMJPRISMA 2020 is current and replaces the 2009 version. 27 items in 7 sections. The item count comes from the article itself; the PRISMA website does not state it.
- EQUATOR Network. About us. read 15 October 2026. View on equator-network.orgThe index to find the right reporting guideline for a study design. Its host institution is not stated in text on its own pages, so none is asserted here.
- The BMJ. Publishing model. read 15 October 2026. View on The BMJA journal's own published figures on what it accepts and what it rejects before review. The page carries no date, so the figures are given as what the BMJ states rather than as of a particular year.
- Meyer HS, Durning SJ, Sklar DP, Maggio LA. Making the First Cut: An Analysis of Academic Medicine Editors’ Reasons for Not Sending Manuscripts Out for External Peer Review. Academic Medicine. 2018;93(3):464–470. doi:10.1097/ACM.0000000000001860 read 15 October 2026. View on USU institutional repositoryA content analysis of editors' reasons on 369 manuscripts rejected before peer review. Read from the repository record rather than the published full text, so the figures are as that record states them. A medical education journal, not a clinical one.
- Bordage G. Reasons reviewers reject and accept manuscripts: the strengths and weaknesses in medical education reports. Academic Medicine. 2001;76(9):889–896. read 15 October 2026. View on a university-hosted full textAn analysis of 1,053 negative reviewer comments across 151 manuscripts. Notable for what topped the list: statistics, described as inappropriate, incomplete or poorly described.
- Clarivate. Journal Citation Reports: the basics. read 15 October 2026. View on ClarivateThe owner's own description. The Journal Impact Factor is calculated by Clarivate, published in Journal Citation Reports and derived from the Web of Science Core Collection.
- Elsevier. What is CiteScore? Scopus support. read 15 October 2026. View on ElsevierCiteScore is calculated by Scopus, which is Elsevier's, from the Scopus database. The support page left its methodology section blank, so no citation window is stated here.
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
Related: CONSORT 2025, item by item · writing an original article · building a literature search.
How Pubrica can help
Pubrica’s medical writers and biostatisticians prepare research papers for submission to selective journals: structuring the manuscript according to the target journal’s instructions, completing the applicable reporting-guideline checklist, reviewing the statistical reporting, and assembling the declarations and registration details that editors check first.